Emerging drug delivery strategies for idiopathic pulmonary fibrosis treatment
Date of Original Version
Idiopathic pulmonary fibrosis (IPF) is a debilitating and fatal condition that causes severe scarring of the lungs. While the pathogenesis of IPF continues to be extensively studied and several factors have been considered, an exact cause has yet to be established. With inadequate treatment options and no cure available, overall disease prognosis is still poor. Existing oral therapies, pirfenidone and nintedanib, may attempt to improve the patients’ quality of life by mitigating symptoms and slowing disease progression, however chronic doses and systemic deliveries of these drugs can lead to severe side effects. The lack of effective treatment options calls for further investigation of restorative as well as additional palliative therapies for IPF. Nanoparticle-based sustained drug delivery strategies can be utilized to ensure targeted delivery for site-specific treatment as well as long-acting therapy, improving overall patient compliance. This review provides an update on promising strategies for the delivery of anti-fibrotic agents, along with an overview of key therapeutic targets as well as relevant emerging therapies currently being evaluated for IPF treatment.
European Journal of Pharmaceutics and Biopharmaceutics
Ghumman, Moez, Dinesh Dhamecha, Andrea Gonsalves, Lauren Fortier, Parand Sorkhdini, Yang Zhou, and Jyothi U. Menon. "Emerging drug delivery strategies for idiopathic pulmonary fibrosis treatment." European Journal of Pharmaceutics and Biopharmaceutics 164, (2021): 1-12. doi:10.1016/j.ejpb.2021.03.017.